Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Mva Investors, Llc Sells 29,000 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Mva Investors, Llc sold 29,000 shares of the company’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $8.57, for a total transaction of $248,530.00. Following the sale, the insider now owns 314,524 shares of the company’s stock, valued at approximately $2,695,470.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Mva Investors, Llc also recently made the following trade(s):

• On Monday, July 1st, Mva Investors, Llc sold 110,731 shares of Tango Therapeutics stock. The shares were sold at an average price of $8.87, for a total transaction of $982,183.97.
• On Thursday, June 6th, Mva Investors, Llc sold 63,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $7.24, for a total transaction of $456,120.00.
• On Friday, May 3rd, Mva Investors, Llc sold 60,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $7.61, for a total transaction of $456,600.00.
• On Wednesday, May 1st, Mva Investors, Llc sold 75,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $7.43, for a total transaction of $557,250.00.

Tango Therapeutics Trading Down 9.9 %

Shares of NASDAQ TNGX opened at $8.11 on Wednesday. The firm has a market cap of $866.02 million, a PE ratio of -7.17 and a beta of 0.83. Tango Therapeutics, Inc. has a 1-year low of $2.88 and a 1-year high of $13.03. The company has a fifty day moving average price of $7.86 and a 200 day moving average price of $9.27.

Tango Therapeutics (NASDAQ:TNGX) last announced its earnings results on Wednesday, May 8th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). The company had revenue of $6.47 million during the quarter, compared to analyst estimates of $7.13 million. Tango Therapeutics had a negative return on equity of 44.35% and a negative net margin of 299.88%. Equities research analysts forecast that Tango Therapeutics, Inc. will post -1.31 EPS for the current year.

Hedge Funds Weigh In On Tango Therapeutics

A number of large investors have recently modified their holdings of TNGX. AJOVista LLC acquired a new position in shares of Tango Therapeutics during the 4th quarter worth about $61,000. Paloma Partners Management Co acquired a new position in shares of Tango Therapeutics during the 1st quarter worth about $80,000. Cowen AND Company LLC acquired a new position in shares of Tango Therapeutics during the 4th quarter worth about $99,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Tango Therapeutics by 12.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,771 shares of the company’s stock worth $102,000 after buying an additional 1,426 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Tango Therapeutics by 421.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,793 shares of the company’s stock worth $117,000 after buying an additional 9,530 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TNGX has been the subject of several research analyst reports. Guggenheim raised shares of Tango Therapeutics to a “strong-buy” rating in a report on Tuesday, May 28th. Wedbush decreased their price target on shares of Tango Therapeutics from $18.00 to $11.00 and set an “outperform” rating for the company in a report on Thursday, May 23rd. HC Wainwright decreased their price target on shares of Tango Therapeutics from $16.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, May 28th. Cantor Fitzgerald initiated coverage on shares of Tango Therapeutics in a report on Thursday, April 4th. They issued an “overweight” rating for the company. Finally, Barclays decreased their price target on shares of Tango Therapeutics from $18.00 to $13.00 and set an “overweight” rating for the company in a report on Friday, May 24th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $14.17.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.